{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:39:01Z","timestamp":1790822341585,"version":"4.1.0"},"reference-count":27,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hybrid MRI linear accelerators (MR-Linac) might enable individualized online adaptation of radiotherapy using quantitative MRI sequences as diffusion-weighted imaging (DWI). The purpose of this study was to investigate the dynamics of lesion apparent diffusion coefficient (ADC) in patients with prostate cancer undergoing MR-guided radiation therapy (MRgRT) on a 1.5T MR-Linac. The ADC values at a diagnostic 3T MRI scanner were used as the reference standard.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and and methods<\/jats:title>\n                    <jats:p>\n                      In this prospective single-center study, patients with biopsy-confirmed prostate cancer who underwent both an MRI exam at a 3T scanner (MRI\n                      <jats:sub>3T<\/jats:sub>\n                      ) and an exam at a 1.5T MR-Linac (MRL) at baseline and during radiotherapy were included. Lesion ADC values were measured by a radiologist and a radiation oncologist on the slice with the largest lesion. ADC values were compared before\n                      <jats:italic>vs<\/jats:italic>\n                      . during radiotherapy (during the second week) on both systems via paired t-tests. Furthermore, Pearson correlation coefficient and inter-reader agreement were computed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of nine male patients aged 67 \u00b1 6 years [range 60 \u2013 67 years] were included. In seven patients, the cancerous lesion was in the peripheral zone, and in two patients the lesion was in the transition zone. Inter-reader reliability regarding lesion ADC measurement was excellent with an intraclass correlation coefficient of (ICC) &gt; 0.90 both at baseline and during radiotherapy. Thus, the results of the first reader will be reported. In both systems, there was a statistically significant elevation of lesion ADC during radiotherapy (mean MRL-ADC at baseline was 0.97 \u00b1 0.18 \u00d7 10\n                      <jats:sup>\u22123<\/jats:sup>\n                      mm\n                      <jats:sup>2<\/jats:sup>\n                      \/s\n                      <jats:italic>vs<\/jats:italic>\n                      . mean MRL-ADC during radiotherapy 1.38 \u00b1 0.3 \u00d7 10\n                      <jats:sup>\u22123<\/jats:sup>\n                      mm\n                      <jats:sup>2<\/jats:sup>\n                      \/s, yielding a mean lesion ADC elevation of 0.41 \u00b1 0.20 \u00d7 10\n                      <jats:sup>\u22123<\/jats:sup>\n                      mm\n                      <jats:sup>2<\/jats:sup>\n                      \/s, p &lt; 0.001). Mean MRI\n                      <jats:sub>3T<\/jats:sub>\n                      -ADC at baseline was 0.78 \u00b1 0.165 \u00d7 10\n                      <jats:sup>\u22123<\/jats:sup>\n                      mm\n                      <jats:sup>2<\/jats:sup>\n                      \/s\n                      <jats:italic>vs<\/jats:italic>\n                      . mean MRI\n                      <jats:sub>3T<\/jats:sub>\n                      -ADC during radiotherapy 0.99 \u00b1 0.175 \u00d7 10\n                      <jats:sup>\u22123<\/jats:sup>\n                      mm\n                      <jats:sup>2<\/jats:sup>\n                      \/s, yielding a mean lesion ADC elevation of 0.21 \u00b1 0.96 \u00d7 10\n                      <jats:sup>\u22123<\/jats:sup>\n                      mm\n                      <jats:sup>2<\/jats:sup>\n                      \/s p &lt; 0.001). The absolute ADC values from MRL were consistently significantly higher than those from MRI\n                      <jats:sub>3T<\/jats:sub>\n                      at baseline and during radiotherapy (p &lt; = 0.001). However, there was a strong positive correlation between MRL-ADC and MRI\n                      <jats:sub>3T<\/jats:sub>\n                      -ADC at baseline (\n                      <jats:italic>r<\/jats:italic>\n                      = 0.798, p = 0.01) and during radiotherapy (\n                      <jats:italic>r<\/jats:italic>\n                      = 0.863, p = 0.003).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Lesion ADC as measured on MRL increased significantly during radiotherapy and ADC measurements of lesions on both systems showed similar dynamics. This indicates that lesion ADC as measured on the MRL may be used as a biomarker for evaluation of treatment response. In contrast, absolute ADC values as calculated by the algorithm of the manufacturer of the MRL showed systematic deviations from values obtained on a diagnostic 3T MRI system. These preliminary findings are promising but need large-scale validation. Once validated, lesion ADC on MRL might be used for real-time assessment of tumor response in patients with prostate cancer undergoing MR-guided radiation therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2023-0020","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T07:13:45Z","timestamp":1687331625000},"page":"184-190","source":"Crossref","is-referenced-by-count":16,"title":["Longitudinal monitoring of Apparent Diffusion Coefficient (ADC) in patients with prostate cancer undergoing MR-guided radiotherapy on an MR-Linac at 1.5 T: a prospective feasibility study"],"prefix":"10.2478","volume":"57","author":[{"given":"Haidara","family":"Almansour","sequence":"first","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology , Eberhard-Karls University , Tuebingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"Schick","sequence":"additional","affiliation":[{"name":"Section for Experimental Radiology, Department of Radiology , Eberhard-Karls University , Tuebingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Nachbar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology , Charit\u00e9 University Medicine Berlin , Berlin , Germany"},{"name":"Section for Biomedical Physics, Department of Radiation Oncology , Eberhard-Karls University , Tuebingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saif","family":"Afat","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology , Eberhard-Karls University , Tuebingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Fritz","sequence":"additional","affiliation":[{"name":"Section for Experimental Radiology, Department of Radiology , Eberhard-Karls University , Tuebingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Thorwarth","sequence":"additional","affiliation":[{"name":"Section for Biomedical Physics, Department of Radiation Oncology , Eberhard-Karls University , Tuebingen , Germany"},{"name":"German Cancer Consortium (DKTK) , Partner Site Tuebingen and German Cancer Research Center (DKFZ) , Heidelberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Zips","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology , Charit\u00e9 University Medicine Berlin , Berlin , Germany"},{"name":"German Cancer Consortium (DKTK) , Partner Site Tuebingen and German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"Department of Radiation Oncology , Eberhard-Karls University , Tuebingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Bertram","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology , Eberhard-Karls University , Tuebingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt-Christian","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology , Eberhard-Karls University , Tuebingen , Germany"},{"name":"Department of Radiation Oncology , RKH Klinikum Ludwigsburg , Ludwigsburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Nikolaou","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology , Eberhard-Karls University , Tuebingen , Germany"},{"name":"Cluster of Excellence iFIT (EXC 2180) \u201cImage Guided and Functionally Instructed Tumor Therapies\u201d , University of Tuebingen , Tuebingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed E","family":"Othman","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology , Eberhard-Karls University , Tuebingen , Germany"},{"name":"Department of Neuroradiology , University Medical Center Mainz , Mainz , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wegener","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology , Eberhard-Karls University , Tuebingen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"2026071211471336710_j_raon-2023-0020_ref_001","doi-asserted-by":"crossref","unstructured":"Mottet N, van den Bergh RCN, Briers E, van den Broeck T, Cumberbatch MG, de Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2021; 79: 243\u201362. doi: 10.1016\/j.eururo.2020.09.042","DOI":"10.1016\/j.eururo.2020.09.042"},{"key":"2026071211471336710_j_raon-2023-0020_ref_002","doi-asserted-by":"crossref","unstructured":"Pathmanathan AU, McNair HA, Schmidt MA, Brand DH, Delacroix L, Eccles CL, et al. Comparison of prostate delineation on multimodality imaging for MR-guided radiotherapy. Br J Radiol 2019; 92: 20180948. doi: 10.1259\/bjr.20180948","DOI":"10.1259\/bjr.20180948"},{"key":"2026071211471336710_j_raon-2023-0020_ref_003","doi-asserted-by":"crossref","unstructured":"Dunlop A, Mitchell A, Tree A, Barnes H, Bower L, Chick J, et al. Daily adaptive radiotherapy for patients with prostate cancer using a high field MR-linac: initial clinical experiences and assessment of delivered doses compared to a C-arm linac. Clin Transl Radiat Oncol 2020; 23: 35\u201342. doi: 10.1016\/j.ctro.2020.04.011","DOI":"10.1016\/j.ctro.2020.04.011"},{"key":"2026071211471336710_j_raon-2023-0020_ref_004","doi-asserted-by":"crossref","unstructured":"Wegener D, Thome A, Paulsen F, Gani C, Boldt J, Butzer S, et al. First experience and prospective evaluation on feasibility and acute toxicity of online adaptive radiotherapy of the prostate bed as salvage treatment in patients with biochemically recurrent prostate cancer on a 1.5 T MR-linac. J Clin Med 2022; 11: 4651. doi: 10.3390\/jcm11164651","DOI":"10.3390\/jcm11164651"},{"key":"2026071211471336710_j_raon-2023-0020_ref_005","doi-asserted-by":"crossref","unstructured":"Gr\u00e9goire V, Guckenberger M, Haustermans K, Lagendijk JJW, M\u00e9nard C, P\u00f6tter R, et al. Image-guidance in radiation therapy for better cure of cancer. Mol Oncol 2020; 14: 1470\u201391. doi: 10.1002\/1878-0261.12751","DOI":"10.1002\/1878-0261.12751"},{"key":"2026071211471336710_j_raon-2023-0020_ref_006","doi-asserted-by":"crossref","unstructured":"Decker G, M\u00fcrtz P, Gieseke J, Tr\u00e4ber F, Block W, Sprinkart AM, et al. Intensity-modulated radiotherapy of the prostate: dynamic ADC monitoring by DWI at 3.0T. Radiother Oncol 2014; 113: 115\u201320. doi: 10.1016\/j.radonc.2014.07.016","DOI":"10.1016\/j.radonc.2014.07.016"},{"key":"2026071211471336710_j_raon-2023-0020_ref_007","doi-asserted-by":"crossref","unstructured":"Thorwarth D, Ege M, Nachbar M, M\u00f6nnich D, Gani C, Zips D, et al. Quantitative magnetic resonance imaging on hybrid magnetic resonance linear accelerators: Perspective on technical and clinical validation. Phys Imaging Radiat Oncol 2020; 16: 69\u201373. doi: 10.1016\/j.phro.2020.09.007","DOI":"10.1016\/j.phro.2020.09.007"},{"key":"2026071211471336710_j_raon-2023-0020_ref_008","doi-asserted-by":"crossref","unstructured":"Almansour H, Afat S, Fritz V, Schick F, Nachbar M, Thorwarth D, et al. Prospective image quality and lesion assessment in the setting of MR-guided radiation therapy of prostate cancer on an MR-linac at 1.5 T: a comparison to a standard 3 T MRI. Cancers 2021; 13: 1533. doi: 10.3390\/cancers13071533","DOI":"10.3390\/cancers13071533"},{"key":"2026071211471336710_j_raon-2023-0020_ref_009","doi-asserted-by":"crossref","unstructured":"Wegener D, Zips D, Thorwarth D, Wei\u00df J, Othman AE, Grosse U, et al. Precision of T2 TSE MRI-CT-image fusions based on gold fiducials and repetitive T2 TSE MRI-MRI-fusions for adaptive IGRT of prostate cancer by using phantom and patient data. Acta Oncologica 2019; 58: 88\u201394. doi: 10.1080\/0284186X.2018.1518594","DOI":"10.1080\/0284186X.2018.1518594"},{"key":"2026071211471336710_j_raon-2023-0020_ref_010","doi-asserted-by":"crossref","unstructured":"Winkel D, Bol GH, Kroon PS, van Asselen B, Hackett SS, Werensteijn-Honingh AM, et al. Adaptive radiotherapy: The Elekta Unity MR-linac concept. Clin Transl Radiat Oncol 2019; 18: 54\u20139. doi: 10.1016\/j.ctro.2019.04.001","DOI":"10.1016\/j.ctro.2019.04.001"},{"key":"2026071211471336710_j_raon-2023-0020_ref_011","unstructured":"[Guideline program oncology. Interdisciplinary guideline of quality S3 for early detection, diagnosis and therapy of the various stages of prostate carcinoma.] [German]. Deutsche Krebsgesellschaft, D.K., AWMF. 2019; Long version 5.1: 345."},{"key":"2026071211471336710_j_raon-2023-0020_ref_012","doi-asserted-by":"crossref","unstructured":"Hallgren KA. Computing inter-rater reliability for observational data: an overview and tutorial. Tutor Quant Methods Psychol 2012; 8: 23\u201334. doi: 10.20982\/tqmp.08.1.p023","DOI":"10.20982\/tqmp.08.1.p023"},{"key":"2026071211471336710_j_raon-2023-0020_ref_013","doi-asserted-by":"crossref","unstructured":"Tamada T, Sone T, Jo Y, Toshimitsu S, Yamashita T, Yamamoto A, et al. Apparent diffusion coefficient values in peripheral and transition zones of the prostate: Comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging 2008; 28: 720\u20136. doi: 10.1002\/jmri.21503","DOI":"10.1002\/jmri.21503"},{"key":"2026071211471336710_j_raon-2023-0020_ref_014","doi-asserted-by":"crossref","unstructured":"van Schie MA, van Houdt PJ, Ghobadi G, Pos FJ, Walraven I, de Boer HCJ, et al. Quantitative MRI changes during weekly ultra-hypofractionated prostate cancer radiotherapy with integrated boost. Front Oncol 2019; 9: 1264. doi: 10.3389\/fonc.2019.01264","DOI":"10.3389\/fonc.2019.01264"},{"key":"2026071211471336710_j_raon-2023-0020_ref_015","doi-asserted-by":"crossref","unstructured":"Wu S, Jiao Y, Zhang Y, Ren X, Li P, Yu Q, et al. Imaging-based individualized response prediction of carbon ion radiotherapy for prostate cancer patients. Cancer Manag Res 2019; 11: 9121\u201331. doi: 10.2147\/CMAR.S214020","DOI":"10.2147\/CMAR.S214020"},{"key":"2026071211471336710_j_raon-2023-0020_ref_016","doi-asserted-by":"crossref","unstructured":"Abdollahi H, Mofid B, Shiri I, Razzaghdoust A, Saadipoor A, Mahdavi A, et al. Machine learning-based radiomic models to predict intensity-modulated radiation therapy response, Gleason score and stage in prostate cancer. Radiol Med 2019; 124: 555\u201367. doi: 10.1007\/s11547-018-0966-4","DOI":"10.1007\/s11547-018-0966-4"},{"key":"2026071211471336710_j_raon-2023-0020_ref_017","doi-asserted-by":"crossref","unstructured":"Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS prostate imaging \u2013 reporting and data system: 2015, version 2. Eur Urol 2016; 69: 16\u201340. doi: 10.1016\/j.eururo.2015.08.052","DOI":"10.1016\/j.eururo.2015.08.052"},{"key":"2026071211471336710_j_raon-2023-0020_ref_018","doi-asserted-by":"crossref","unstructured":"Thorwarth D, Low DA. Technical challenges of real-time adaptive MR-guided radiotherapy. Front Oncol 2021; 11: 634507. doi: 10.3389\/fonc.2021.634507","DOI":"10.3389\/fonc.2021.634507"},{"key":"2026071211471336710_j_raon-2023-0020_ref_019","doi-asserted-by":"crossref","unstructured":"Boeke S, M\u00f6nnich D, van Timmeren JE, Balermpas P. MR-guided radiotherapy for head and neck cancer: current developments, perspectives, and challenges. Front Oncol 2021; 11: 616156. doi: 10.3389\/fonc.2021.616156","DOI":"10.3389\/fonc.2021.616156"},{"key":"2026071211471336710_j_raon-2023-0020_ref_020","doi-asserted-by":"crossref","unstructured":"Boldrini L, Intven M, Bassetti M, Valentini V, Gani C. MR-guided radiotherapy for rectal cancer: current perspective on organ preservation. Front Oncol 2021; 11: 619852. doi: 10.3389\/fonc.2021.619852","DOI":"10.3389\/fonc.2021.619852"},{"key":"2026071211471336710_j_raon-2023-0020_ref_021","doi-asserted-by":"crossref","unstructured":"Yang Y, Cao M, Sheng K, Gao Y, Chen A, Kamrava M, et al. Longitudinal diffusion MRI for treatment response assessment: preliminary experience using an MRI-guided tri-cobalt 60 radiotherapy system. Med Phys 2016; 43: 1369\u201373. doi: 10.1118\/1.4942381","DOI":"10.1118\/1.4942381"},{"key":"2026071211471336710_j_raon-2023-0020_ref_022","doi-asserted-by":"crossref","unstructured":"Shaverdian N, Yang Y, Hu P, Hart S, Sheng K, Lamb J, et al. Feasibility evaluation of diffusion-weighted imaging using an integrated MRI-radiotherapy system for response assessment to neoadjuvant therapy in rectal cancer. Br J Radiol 2017; 90: 20160739. doi: 10.1259\/bjr.20160739","DOI":"10.1259\/bjr.20160739"},{"key":"2026071211471336710_j_raon-2023-0020_ref_023","doi-asserted-by":"crossref","unstructured":"Lawrence LSP, Chan RW, Chen H, Keller B, Stewart J, Ruschin M, et al. Accuracy and precision of apparent diffusion coefficient measurements on a 1.5 T MR-Linac in central nervous system tumour patients. Radiother Oncol 2021; 164: 155\u201362. doi: 10.1016\/j.radonc.2021.09.020","DOI":"10.1016\/j.radonc.2021.09.020"},{"key":"2026071211471336710_j_raon-2023-0020_ref_024","doi-asserted-by":"crossref","unstructured":"Habrich J, Boeke S, Nachbar M, Nikolaou K, Schick F, Gani C, et al. Repeatability of diffusion-weighted magnetic resonance imaging in head and neck cancer at a 1.5 T MR-Linac. Radiother Oncol 2022; 174: 141\u20138. doi: 10.1016\/j.radonc.2022.07.020","DOI":"10.1016\/j.radonc.2022.07.020"},{"key":"2026071211471336710_j_raon-2023-0020_ref_025","doi-asserted-by":"crossref","unstructured":"Habrich J, Boeke S, Nachbar M, Nikolaou K, Schick F, Gani C, et al. Longitudinal correlations between intravoxel incoherent motion (IVIM) and dynamic contrast-enhanced (DCE) MRI during radiotherapy in prostate cancer patients. Front Oncol 2022; 12: 897130. doi: 10.3389\/fonc.2022.897130","DOI":"10.3389\/fonc.2022.897130"},{"key":"2026071211471336710_j_raon-2023-0020_ref_026","doi-asserted-by":"crossref","unstructured":"van der Heide UA, Houweling AC, Groenendaal G, Beets-Tan RG, Lambin P. Functional MRI for radiotherapy dose painting. Magn Reson Imaging 2012; 30: 1216\u201323. doi: 10.1016\/j.mri.2012.04.010","DOI":"10.1016\/j.mri.2012.04.010"},{"key":"2026071211471336710_j_raon-2023-0020_ref_027","doi-asserted-by":"crossref","unstructured":"Kooreman ES, van Houdt PJ, Keesman R, Pos FJ, van Pelt VWJ, Nowee ME, et al. ADC measurements on the Unity MR-linac - A recommendation on behalf of the Elekta Unity MR-linac consortium. Radiother Oncol 2020; 153: 106\u201313. doi: 10.1016\/j.radonc.2020.09.046","DOI":"10.1016\/j.radonc.2020.09.046"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2023-0020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:03:41Z","timestamp":1783901021000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2023-0020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,6,21]]},"published-print":{"date-parts":[[2023,6,1]]}},"alternative-id":["10.2478\/raon-2023-0020"],"URL":"https:\/\/doi.org\/10.2478\/raon-2023-0020","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]}}}